CD274 and endometrial cancer: However, in a post-hoc analysis from the phase I GARNET Trial (NCT02715284), endometrial cancer patients with high TMB (defined as ≥10 mutations/megabase on next generation sequencing) demonstrated higher overall response rates to the PD-L1 blockade by dostarlimab [102].